On September 5, 2022 Chiome Bioscience Inc.("Chiome") reported that Chiome will present preclinical data supporting development of its proprietary anti-CDCP1 antibody drug conjugate named PCDC as a therapeutic candidate at the 13th World ADC San Diego 2022 (venue: September 6th-9th, 2022) (Press release, Chiome Bioscience, SEP 5, 2022, View Source [SID1234625708]). As this anti-CDCP1 antibody is characterized for its internalization into cancer cell we have tested several payloads and conjugates in vitro and in vivo. Chiome will present data on anti-CDCP1 antibody conjugated with several payloads such as PBD, MMAE, and amanitin. Each ADC has shown significant anti-tumor activities in vitro and in vivo on multiple models. In addition, Non-GLP toxicity study using cynomolgus monkey showed that amanitin conjugated antibody exhibited tolerability in the expected therapeutics dose.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
➢ Poster Presentation
Date: September 7th, 2022 AM10:00-PM7:00
Place: Sheraton San Diego Hotel and Marina
Title: Anti-CDCP1 antibodies for drug conjugate
➢ World ADC San Diego 2022 Website
View Source
World ADC is one of the most comprehensive conferences in ADC fields from early discovery to clinical and manufacturing. It is held annually, and researchers and pharma companies around the world will participate. This year it is held for the first time in-person since 2019 with 600+ participants at the forefront of ADC R&D.
PCDC is the project on humanized monoclonal antibody that targets CDCP1, highly expresses in broad range of solid tumors, including lung, breast, colorectal, pancreas, prostate, ovarian cancers. Chiome has been studying PCDC as one of our therapeutic pipelines. Patent applications for this antibody has already been submitted.
Information
Chiome is granted access to the ATACⓇ platform, antibody targeted amanitin conjugate technology, developed by Heidelberg Pharma GmbH (Ladenburg, Germany). Amanitin is a toxin found in several species of mushrooms. With ATAC platform, amanitin is conjugated to our anti-CDCP1 antibody. In the preclinical study, the amanitin conjugated anti-CDCP1 antibody has shown significant anti-tumor activities in vitro and in vivo. Chiome is actively working to find a partner.